Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy.

Authors

Jacques E. Rossouw, National Institutes of Health, Bethesda, MD
Ross Prentice, Fred Hutchinson Cancer Research Center, Seattle, WA
Joann E. Manson, Brigham and Women's Hospital, Boston, MA
Aaron K. Aragaki, Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, WA
Judith Hsia, AstraZeneca
Lisa W. Martin, George Washington UniversityFollow
Lewis H. Kuller, University of Pittsburgh
Karen C. Johnson, University of TennesseeFollow
Charles B. Eaton, Brown University
Rebecca Jackson, Ohio State University
Maurizio Trevisan, University of Nevada, Las Vegas
Matthew A. Allison, University of California - San Diego
Ron C. Hoogeveen, Baylor College

Document Type

Journal Article

Publication Date

9-2012

Journal

Circulation

Volume

Volume 126, Issue 13

Inclusive Pages

1577-1586

Keywords

Cholesterol; LDL--blood; Coronary Disease--epidemiology; Estrogen Replacement Therapy--adverse effects; Hydroxycholesterols--blood; Menopause--blood

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Rossouw, J. E., Prentice, R. L., Manson, J. E., Aragaki, A. K., Hsia, J., Martin, L. W., . . . Hoogeveen, R. C. (2012). Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy. Circulation, 126(13), 1577-1586.

Peer Reviewed

1

Open Access

1